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Protection against a malaria infection can be achieved by immunization with
live-attenuated Plasmodium sporozoites and while the precise mechanisms of protection
remain unknown, T cell responses are thought to be critical in the elimination of infected
liver cells. In cancer immunotherapies, agonistic antibodies that target T cell surface
proteins, such as CD27, OX40 (CD134), and 4-1BB (CD137), have been used to enhance
T cell function by increasing co-stimulation. In this study, we have analyzed the effect of
agonistic OX40 monoclonal antibody treatment on protective immunity induced in mice
immunized with genetically attenuated parasites (GAPs). OX40 stimulation enhanced
protective immunity after vaccination as shown by an increase in the number of protected
mice and delay to blood-stage infection after challenge with wild-type sporozoites.
Consistent with the enhanced protective immunity enforced OX40 stimulation resulted
in an increased expansion of antigen-experienced effector (CD11ahiCD44hi) CD8+ and
CD4+ T cells in the liver and spleen and also increased IFN-γ and TNF producing CD4+
T cells in the liver and spleen. In addition, GAP immunization plus α-OX40 treatment
significantly increased sporozoite-specific IgG responses. Thus, we demonstrate that
targeting T cell costimulatory receptors can improve sporozoite-based vaccine efficacy.
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INTRODUCTION
Malaria remains a major threat to the lives of more than 3 billion people world-wide and there
remains a pressing but unmet need for an effective vaccine, which can provide sustained protection
against either infection or disease. Despite three decades of clinical testing different (recombinant)
sub-unit vaccines, only modest protection has been reported so far (Hoffman et al., 2015; Tinto
et al., 2015; White et al., 2015; Mahmoudi and Keshavarz, 2017) and this has renewed an interest
in whole parasite-based vaccine approaches (Pinzon-Charry and Good, 2008; Hollingdale and
Sedegah, 2017). It was first shown in rodent models of malaria that complete protection against
infection can be obtained by vaccination using live attenuated sporozoites (Nussenzweig et al.,
1967, 1969). Sterile protection against a malaria infection was also demonstrated in humans
Othman et al. OX40 Stimulation Enhances GAP Immunization
after immunization with Plasmodium falciparum sporozoites,
either attenuated by radiation or administered under
chemoprophylaxis (Hoffman et al., 2002; Roestenberg et al.,
2009; Seder et al., 2013). A prerequisite for induction of
protective immunity using sporozoite-based vaccines is that
sporozoites retain their capacity to invade liver cells after their
administration. The most advanced live-attenuated vaccine is
based on radiation-attenuated sporozoites (PfSPZ-Vaccine),
which is currently being evaluated both in the clinic and in
field trials (Richie et al., 2015; Sissoko et al., 2017). In rodent
models, immunization with sporozoites of genetically-attenuated
parasites (GAP) can induce similar or even better levels of
protective immunity compared to irradiated sporozoites (Irr-
Spz) (Butler et al., 2011; Othman et al., 2017). Rodent GAP
studies have been critical in the creation of two P. falciparum
GAP-based vaccines that are currently undergoing clinical
evaluation (Khan et al., 2012; Mikolajczak et al., 2014; van
Schaijk et al., 2014).
A number of studies from both the clinic and the
field have shown that Irr-Spz can generate strong protective
immunity in humans (Ishizuka et al., 2016; Lyke et al., 2017;
Sissoko et al., 2017). However, in order to achieve high level
protective immunity multiple immunizations with high doses of
attenuated sporozoites are required (Seder et al., 2013; Sissoko
et al., 2017). The high numbers of sporozoites required for
vaccination increases the costs of sporozoite-based vaccines and
complicates the production and application of such vaccines for
mass administration in malaria-endemic countries. The major
challenge is to produce a highly immunogenic live-attenuated
vaccine, which requires the fewest attenuated sporozoites per
dose and the fewest doses to induce sustained sterile protection
against a malaria infection.
While the precise mechanisms of protection mediated by
immunization with attenuated sporozoites remain unknown,
T cells appear to be critical for protection and in particular
CD8+ T cells are thought to play a major role in eliminating
infected hepatocytes. Early rodent studies using Irr-Spz have
demonstrated a vital role for CD8+ T cells (Schofield et al.,
1987; Weiss et al., 1988). Recent mechanistic investigations into
protective immune responses induced by immunization with
attenuated sporozoites have demonstrated diverse and robust
immune responses that encompasses both CD8+ and CD4+ T
cells, as well as a significant contribution from antibodies (Doll
andHarty, 2014; Van Braeckel-Budimir et al., 2016). Nonetheless,
CD8+ T cells are considered to be the main effector cells in
eliciting protection after sporozoites immunization (Silvie et al.,
2017).
Recently, cancer immunotherapies have employed antibodies
that target proteins on the surface of T cells, as treatment
with these antibodies have been shown to restore, expand and
enhance the function of tumor-reactive T cells. The antagonistic
antibodies targeting CTLA-4 and PD-1 have been used to block
inhibitory signals to T cells (Curran et al., 2010; Wolchok
et al., 2013), while agonistic antibodies targeting CD27, OX40,
and 4-1BB on CD4+ and CD8+ T cells have been used to
increase costimulatory signals (Croft, 2003; Dawicki et al., 2004;
Melero et al., 2007). These immunostimulatory antibodies have
been shown to improve the control of tumors and this was
associated with an increase in tumor-specific T cell function
(Schaer et al., 2014). In this study, we have analyzed the effect
of agonistic OX40 monoclonal antibody (OX40 mAb) treatment
on protective immunity induced in mice by immunization with
GAP sporozoites.We immunized BALB/cmice using sporozoites
of a P. yoelii GAP, an established rodent model to evaluate
GAP vaccination (Butler et al., 2011). We found that OX40
mAb (α-OX40) treatment enhanced protective immunity, which
was correlated with an expansion effector CD4+ and CD8+ T
cell subsets, in both the liver and the spleen. In addition α-
OX40 treatment induced the production of effector cytokine-
producing T cells in the liver and spleen. Our results indicate
that targeting costimulatory receptors on T cells can be used to
improve sporozoite-based vaccine potency and in turn could be
used to improve GAP vaccine implementation by reducing the
numbers of sporozoites required to induce protective immunity.
MATERIALS AND METHODS
Experimental Animals and Parasites
Female BALB/cByJ mice (6–7 weeks; Charles River, NL and
Harlan, Bicester, UK) were used. All animal experiments of this
study were approved by the Animal Experiments Committee of
the Leiden University Medical Center (DEC 13132 and 14307).
The Dutch Experiments on Animal Act is established under
European guidelines (EU directive no. 86/609/EEC regarding the
Protection of Animals used for Experimental andOther Scientific
Purposes). All experiments were performed in accordance with
relevant guidelines and regulations. Two P. yoelii (Py) lines
were used: (i) the reference “wild type” Py17XNL parasite line
1971cl1 (PyWT; PyGFP-luccon; line RMgm-689; www.pberghei.
eu (Lin et al., 2011); which contains the fusion gene gfp-luc
gene under control of the constitutive eef1α promoter integrated
into the silent 230p gene locus (PY17X_0306600) and does
not contain a drug-selectable marker and (ii) the “genetically
attenuated parasite” Py17XNL mutant that lacks the gene fabb/f
(3-oxoacyl-acyl-carrier protein synthase; PY17X_1126500). This
mutant (1PyFabBF-GFP-Luccon; Py1fabb/f ; mutant RMgm-
4109; www.pberghei.eu) was generated in the reference line
1971cl1 (Haeberlein et al., 2017) by standard methods of
transfection using a DNA construct that targets the fabb/f gene
containing hdhfr/fcu selectable marker cassette by double cross-
over integration.
Mosquito Infection, Analysis of Oocysts
and Preparation and Injection of
Sporozoites
Sporozoites were obtained by manual dissection of the salivary
glands of infected female Anopheles stephensi mosquitoes 14
days after feeding on infected mice. Mosquitoes were kept at a
temperature of 24.5◦C and 80% humidity. Salivary glands were
collected in RPMI medium, homogenized and filtered (40µm
Falcon, Corning, Amsterdam, NL). The free sporozoites were
counted in a Bürker counting chamber using phase-contrast
microscopy. For intravenous (IV) administration sporozoites
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were suspended in RPMI medium and per mouse 200 µl was
injected into the tail vein. Oocyst numbers in dissected midguts
from infected mosquitoes were established 8 days after feeding
using light-microscopy.
Determination of Parasite Liver Load by
Real Time in Vivo Imaging
Parasite liver loads in live mice after immunization and after
challenge were quantified by real time in vivo imaging as
previously described (Annoura et al., 2013). Liver stages were
visualized and liver loads quantified by measuring luciferase
activity of parasites in whole bodies of mice at 44 h after
injection of sporozoites using the IVIS Lumina II Imaging
System (Perkin Elmer Life Sciences, Waltham, USA). During
measurements mice were anesthetized using the isofluorane-
anesthesia system (XGI-8, Caliper Life Sciences, Hopkinton,
USA). D-luciferin was dissolved in PBS (100mg/kg; Caliper
Life Sciences, USA) and injected subcutaneously in the neck.
Measurements were performed within 8min after the injection
of D-luciferin. Quantitative analysis of bioluminescence of whole
bodies was performed by measuring the luminescence signal
intensity using the ROI (region of interest) settings of the Living
Image R© 4.4 software.
Immunization Protocol and Determination
of Prepatent Period After Challenge
For the immunization experiments mice were immunized using
isolated Py1fabb/f sporozoites according to the immunization
protocols described in the Results section. Blood of immunized
mice was analyzed for possible breakthrough blood infections by
Giemsa-stained blood smears 1 day before challenge with PyWT
sporozoites. Immunizedmice and naïve controls were challenged
14 days after the last immunization with 3000 (i.e., 3 × 103)
PyWT sporozoites. Challenged mice were monitored for blood-
stage infections by Giemsa-stained blood smears made at day 4 to
14 after challenge. The prepatent period (measured in days after
sporozoites challenge) is defined as the day when a blood stage
infection with a parasitemia of 0.5–2% is observed (van Schaijk
et al., 2014). Organs (and serum) used for immunological analysis
were collected from the mice at day 7 after immunization or at 7
days after challenge.
OX40 Monoclonal Antibody (mAb)
Treatment
Mice were treated with 200µg of OX40 mAb (clone RM134L;
Bio X Cell, West Lebanon, NH, United States) in 200 µl PBS and
administrated by intraperitoneal injection (IP) either at day 0 or
one day after prime or boost immunization.
Treatment With ARTC2-Blocking
Nanobodies
Immunized mice and naïve controls were treated with 50
µg ARTC2-blocking nanobodies (Biolegend) in 200 µl PBS
administered by IP injection 30min before sacrificing mice for
collection of the organs for the immunological assays.
Liver Perfusion and Purification of Liver
and Spleen Cells
Mice were perfused under anesthesia by intracardiac injection
of 20ml PBS (B. Braun, Oss, NL). Perfused livers were minced
in small pieces and digested for 30min at 37◦C in Dulbecco’s
Modified Eagle Medium (Thermo Fisher Scientific, Breda, NL)
containing 250U/ml collagenase and 20µg/ml DNase. Hepatic
leukocytes was obtained by passing the digested tissue through a
70µM cell-strainer (BD Biosciences. San Diego, CA) and Percoll
gradient. For spleens, splenocytes were harvested by mincing the
tissue through a 70µm cell strainer.
Cell Surface Staining, Intracellular
Staining, and Flow Cytometry
For cell surface staining, hepatic leukocytes and splenocytes were
resuspended in staining buffer (PBS, 2% FCS. 0.05% sodium
azide) and incubated with fluorescent conjugated Abs for 30min
at 4◦C. For intracellular cytokine staining, hepatic leukocytes and
splenocytes were re-stimulated in vitro with medium containing
5 × 104 PyWT sporozoites for 24 h in 96-well flat-bottom plates
(1.5 × 106 hepatic leukocytes and splenocytes per well) as
described (Arens et al., 2011). In order to improve re-stimulation
and to increase the number of antigen-presenting cells, 1.5× 105
of splenocytes were added at the start of the cultures to all wells.
Twenty hours after incubation 1µg/ml brefeldin A (Golgiplug;
BD Pharmingen) was added to all wells. After re-stimulation,
cells were transferred to U-bottom 96-well plates, and the cell
surface stained with fluorescent conjugated Abs at 4◦C for 30min
in staining buffer. After washing, cells were fixed with 0.5%
paraformaldehyde at 4◦C for 30min, followed by intracellular
staining for cytokines at 4◦C for 30min in Perm/Wash buffer (BD
Biosciences). After washing and resuspending in staining buffer,
cells were acquired using a BD LSRII flow cytometer and data
were analyzed using FlowJo software (Tree Star). Fluorochrome-
conjugated mAbs specific for CD3, CD4, CD8, CD44, CD11a,
KLRG1, CD134, IFN-γ, IL-2, and TNF were purchased from BD
Biosciences or eBioscience (San Diego, CA).
Elisa
Enzyme-linked immunosorbent assay (ELISA) plates (Corning,
Inc.) were coated overnight at 4◦C by adding 1 × 104 Py1fabb/f
sporozoite lysate diluted in 100 µl NaHCO3 buffer (pH 9,6) per
well. Plates were washed three times with PBS-T (0.05% Tween
20 in 1×PBS) prior to blocking for 2 h in blocking buffer (1%
BSA in PBS-T). Next, sera was diluted in blocking buffer at
1:100 for sporozoite lysate per well. Plates were incubated for 3 h
at room temperature before washing as described above. Next,
100µl of a 1:5000 dilution of horseradish peroxidase (HRP)
conjugated anti-mouse IgG (Jackson Immuno-Research) was
added and incubated for an additional 1 h at room temperature.
Finally, plates were washed again and 100µl of TMB Substrate
solution (Thermo Scientific) was added for 5min. The reaction
was stopped by addition of 50µl of 0.5N sulfuric acid prior to
measurement of absorbance at 450 nm using a Multiskan FC
(Thermo Scientific) microplate reader.
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Statistics
All data are calculated using the GraphPad Prism software
package 5.04 (GraphPad Software, Inc). For ELISA, cell
surface and intracellular staining analysis, statistical analysis
was performed using the unpaired Student’s t-test. For the
survival analysis, statistical analyzes to determine differences in
protection after challenge were performed using a Kaplan–Meier
survival plot, and survival curves were compared using the log-
rank (Mantel-Cox) test. Survival was considered as the complete
absence of parasites in blood. The significance threshold were
0.05 in all analysis.
RESULTS
Establishing a Gap Spz-BALB/C
Immunization-Challenge Protocol to
Investigate Strategies to Improve Gap
Immunization
The P. yoelii-BALB/c parasite-mouse combination is a well-
establishedmodel used to analyze vaccines that target sporozoites
or liver-stage parasites. To analyze protective immunity induced
after GAP immunization, we used sporozoites of P. yoelli
1fabb/f GAP parasites. The Py1fabb/f parasites (GAP) lacks
the fabb/f gene (PY17X_1126500) and arrest late into liver
stage development (Vaughan et al., 2009; Haeberlein et al.,
2017). This GAP produces oocysts and salivary gland sporozoites
comparable to the wild-type parent P. yoelii 17XNL PyGFP-
luccon line (PyWT) (Figure S1A). Both GAP and PyWT
sporozoites express the fusion protein GFP-Luciferase under
control of the constitutive eef1a promoter, permitting the
determination of parasite liver loads in live mice by real
time bioluminescence imaging (Haeberlein et al., 2017). The
GAP sporozoites exhibit levels of in vivo liver infection that
are comparable to PyWT sporozoites (Figure S1B), however,
these GAP sporozoites are unable to initiate a blood infection
(Table S1).
Protective immunity in immunized mice after challenge with
WT sporozoites is defined either by the number of mice that
are completely protected from infection or by the delay in time
taken to establish a blood stage infection, i.e., the prepatent
period (time-to-event analysis) (O’Meara et al., 2007). In this
study the prepatent period is defined as the number of days to
reach a 0.5-2% parasitemia after PyWT sporozoites challenge
as previously described (van Schaijk et al., 2014). Previously
we had established that a primary immunization followed by
boost immunization with 1 × 104 GAP sporozoites induced
sterile protection in more than 90% of BALB/c mice against
challenge with 1 × 104 PyWT sporozoites (Haeberlein et al.,
2017). To examine putative enhancing protective immunity
of treatment with adjuvants/immunomodulatory molecules we
attempted to identify a “sub-saturating” immunization regiment
by immunizing mice with only a single dose of GAP parasites.
Mice were immunized with either 1, 2.5, or 5 × 104 GAP
sporozoites and then challenged 14 days later with 3× 103 PyWT
sporozoites (Figure 1A). A single immunization with all three
doses resulted in none of the mice being completely protected.
FIGURE 1 | Suboptimal protection after GAP immunization and effect of
α-OX40 treatment on prepatent period after infecting mice with wild type
(PyWT) sporozoites. (A) Protection assays performed in groups of BALB/c
mice (n = 5 per group) immunized with as single dose of 1, 2.5, or 5 × 104
GAP sporozoites and challenged 14 days later with 3 × 103 PyWT
sporozoites. Challenged mice were monitored for blood-stage infections. The
Kaplan-Meier curves illustrate the prepatent period (day at which a parasitemia
of 0.5–2% is observed). Immunization with 2.5 and 5 × 104 GAP sporozoites
resulted in a significant longer prepatent period compared to control,
non-immunized mice [Log-Rank (Mantel-Cox) test]. (B) Effect of α-OX40
treatment on parasite development in liver and blood. BALB/c mice were
treated with α-OX40 on day 0 and infected with 3.0 × 103 PyWT sporozoites
13 days later. Infected mice were monitored for blood-stage infections. The
Kaplan-Meier curves illustrate that there was no significant differences were
observed in prepatent period between α-OX40 treated mice (n = 15) and
control, non-treated mice (n = 8) in two experiments.
We observed a maximum of 1 day delay in prepatent period in
immunized mice compared to naïve mice. Since the blood stage
multiplication rate is 10× per 24 h, a 1 day delay in the prepatent
period of blood stage infection represents 90% reduction in the
infection in the liver (Janse et al., 2006). The immunization
with 2.5 and 5 × 104 GAP sporozoites resulted in a significance
longer prepatent period (“survival”; p = 0.014 and p = 0.025,
respectively) compared to naïve mice after challenge with PyWT
sporozoites. Since we did not observe a major difference between
the dose of 2.5 and 5 × 104, we choose the protocol of 2.5 ×
104 GAP immunization followed by 3 × 103 PyWT sporozoites
challenge, to analyze the effect of α-OX40 treatment on protective
immunity.
In addition, we performed an experiment to analyze the
possible effect of treatment with α-OX40 in naive mice on liver
and/or blood stage infection. Naïve mice treated with 200 µg of
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α-OX40 in 200 µl PBS by intraperitoneal injection (IP) and non-
treated mice were challenged with PyWT sporozoites 14 days
after treatment. No differences in prepatent period were observed
between treated and untreated mice (Figure 1B), indicating that
α-OX40 treatment has no effect on growth/multiplication of
PyWT parasites in both the liver and blood in non-immunized
mice.
α-OX40 Treatment Increases the Protective
Immunity in Mice Immunized With a Single
Gap Immunization
To determine whether OX40 is expressed on activated T cells
in mice immunized with 2.5 × 104 P. yoelii fabb/f GAP
sporozoites, we determined the OX40 cell surface expression at
day 3 post-immunization. OX40 expression was clearly detected
on activated (CD44hi) CD4+ and CD8+ T cells in the liver
(Figure 2A). In the spleen, the expression of OX40 on activated
CD4+ T cells was also observed, albeit at lower levels compared
to activated liver CD4+ T cells whereas OX40 expression on
activated splenic CD8+ T cells was not detected (Figure 2A).
These data show that GAP immunization is associated with
the upregulation of co-stimulatory OX40 receptor on CD4+
and CD8+ T cells. Therefore to examine if α-OX40 treatment
enhances protective immune responses after GAP vaccination,
we treated mice with α-OX40 1 day after they were immunized
with a single dose of 2.5 × 104 GAP sporozoites as described
above (Figure 2B). As expression of OX40 is upregulated after
antigen recognition, we scheduled α-OX40 administration 1 day
after the immunization (Aspeslagh et al., 2016). Immunized
mice were injected intraperitoneally with 200µg α-OX40 in
200 µl PBS by IP injection. In two experiments we observed
an increase in protective immunity in GAP-immunized plus α-
OX40 mice (Figure 2C). In the control groups of mice, naïve
and GAP-immunized but not OX40 treated, none of the mice
were protected against PyWT sporozoites challenge and all mice
became patent at day 5 or 6 in two experiments. In contrast, in
the two groups of GAP-immunized plus α-OX40 treated mice,
a total of 4 out of 15 (26.7%) mice were completely protected
and in 9 of the remaining 11 mice (60%) PyWT parasites
emerged in the blood 1 day later than GAP-immunized mice
and naive mice (Figure 2C). The vaccination of GAP with α-
OX40 induced a significant increase in protection compared
to immunization with only GAP parasites in both independent
experiments (∗p= 0.011 and ∗∗p= 0.0017).
α-OX40 Treatment After a Single Gap
Immunization Results in an Increase of
Effector (CD44hi CD11ahi) CD4+ T Cells in
Both Liver and Spleen
One week after immunization, organs and blood were collected
from mice that were immunized with a single dose of 2.5 ×
104 GAP sporozoites either with or without α-OX40 treatment
(Figure 3A). In all immunized mice we observed a significant
and strong increase in total white blood cells (WBCs) and
CD4+/CD8+ T cells compared to the naïve control mice.
FIGURE 2 | α-OX40 treatment increases the protective immunity in mice that
received a single GAP immunization. (A) OX40 expression on activated
CD44hi CD4+ and CD44hi CD8+ T cells in the spleen and liver at day 3 after
immunization. Flow cytometric histograms indicate OX40 expression (red) and
fluorescence minus-one (FMO) controls (blue). (B) The time line shows
immunization of BALB/c mice with GAP sporozoites (2.5 × 104), α-OX40
treatment and challenge with wild type (PyWT) sporozoites (3 × 103).
Challenged mice were monitored for blood-stage infections from day 18
onwards to determine the prepatent period. (C) The Kaplan-Meier curves
illustrate the prepatent period (day at which a parasitemia of 0.5–2% is
observed). Data show representative from 2 independent experiments with (i) 5
and (ii) 10 mice per group: Naïve vs. GAP not significant (n.s.); GAP + α-OX40
vs. GAP; GAP + α-OX40 vs. Naïve, respectively in both experiments.
Strikingly, we observed only in the GAP-immunized plus α-
OX40 treated mice a significant increase (∗∗p =0.0023) in
CD4+ T cell numbers in the liver compared to GAP-immunized
mice (Figure 3B). We analyzed the phenotype of the antigen-
experienced effector T cells using CD44 and CD11a as markers
(Rai et al., 2009; Schmidt et al., 2010; Cooney et al., 2013).
When we compared effector (CD44hiCD11ahi) CD8+ and CD4+
T cells we found that in both the spleen and the liver of
GAP-immunized plus α-OX40 treated mice the number of
(CD44hiCD11ahi) CD4+ T cells were significantly increased
(∗p = 0.044 and ∗∗∗p = 0.0004; respectively), compared to GAP-
immunized mice. No significant differences were observed in
(CD44hiCD11ahi) CD8+ T cells in α-OX40 treated or untreated
GAP-immunized mice, either in the liver or spleen (Figure 3C).
Combined these results show that the administration of α-OX40
after a priming GAP immunization enhances the number of
antigen-experienced effector CD4+ T cells in both the liver and
spleen.
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FIGURE 3 | α-OX40 treatment after a single GAP immunization results in an increase of effector (CD44hiCD11ahi) CD4+ T cells in both liver and spleen. (A) The time
line showing immunization of 2 groups of BALB/c mice with GAP sporozoites (2.5 × 104) that were treated or not treated with α-OX40 one day after immunization. T
cells were collected from the liver and spleen at day 7 and analyzed for phenotype analysis at day 7 or for cytokine expression at day 8 after in vitro re-stimulation with
whole sporozoites. (B) The total number of WBC, CD8+ and CD4+ T cells in liver and spleen of different groups of mice. Significant differences in total WBC
(*p = 0.03) and CD4+ T cells (**p = 0.0023) were observed between the livers of α-OX40 treated and non-treated mice. Representative data is shown from 2
independent experiments with 6 mice per group. (C) The upper panel shows the percentages of (CD44hiCD11ahi) T cells of total CD8+ and CD4+ T cells in liver and
spleen in the different groups of mice. The lower panel shows the total number of (CD44hiCD11ahi) CD8+ and (CD44hiCD11ahi) CD4+ T cells in liver and spleen.
A significant increase of (CD44hiCD11ahi) CD4+ cells was observed in both liver and spleen of mice immunized with GAP plus α-OX40 compared to only
GAP-immunized mice (***p = 0.0004 and *p = 0.044, respectively). Representative data is shown from 2 independent experiments with 6 mice per group. Significant
difference by unpaired t-test is indicated by not significant (n.s.) and significant; *p < 0.05 or **p < 0.01, ***p < 0.001, ****p < 0.0001.
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FIGURE 4 | Prime-boost GAP immunization plus α-OX40 during the boost provokes the expansion of total WBC, CD8+ and CD4+ T cell numbers in the liver and
spleen. (A) Time line showing immunization of 2 groups of BALB/c mice with GAP sporozoites (2.5 × 104). Both groups received a prime (day 0) and boost (day 14)
immunization, and were either treated or not treated with α-OX40 one day after the boost immunization. T cells were collected from the liver and spleen at day 7 for
phenotype analysis at day 7 or for cytokine expression at day 8 after in vitro re-stimulation with whole sporozoites. (B) The total number of WBC, CD8+ and CD4+ T
cells in liver and spleen of different groups of mice. Significant differences were observed between total WBC (*p = 0.035 and **p = 0.001) and CD4+ T cells
(*p = 0.0625 and *p = 0.019) collected from the liver and spleen of treated and untreated mice. In addition, a significant difference in total CD8+ T cells (*p = 0.019)
was observed between livers of treated and untreated mice. Representative data is shown from 2 independent experiments with 6 mice per group. Significant
difference by unpaired t-test is indicated as not significant (n.s.) or significant; *p < 0.05 or **p < 0.01.
Increased Effector T Cell Formation by
α-OX40 Treatment After Prime-Boost Gap
Immunization
In order to examine the effect of α-OX40 treatment on both the
formation and recall of the adaptive immune response after GAP
vaccination, we adopted a prime-boost immunization strategy.
Specifically, we immunized mice initially with a 2.5 × 104 GAP
sporozoites followed 2 weeks later by a boost with 2.5 × 104
GAP sporozoites (Figure 4). This GAP immunization schedule
provides 90–100% sterile protective immunity in BALB/c mice
(Butler et al., 2011). α-OX40 treatment, as described above, was
performed 1 day after the boost immunization as described for
a vaccination protocol against mouse cytomegalovirus infection
(Panagioti et al., 2017), and organs and blood collected 1 week
after the boost immunization. In GAP-immunized plus α-OX40
treated mice we observed a strong significant increase in total
WBCs in both the spleen and the liver (∗∗p = 0.001) and liver
(∗p = 0.035) compared to GAP-immunized mice (Figure 4). We
also observed an increase in total CD4+ and CD8+ T cells in
GAP-immunized plus α-OX40 mice in the liver (p = 0.0625,
∗p = 0.043 respectively). In the spleen we only observed a
significant increase in total CD4+ T cells (∗p = 0.019) but
not in the CD8+ T cells in GAP-immunized plus α-OX40
treated mice compared to GAP-immunized mice. In both the
spleen and the liver of GAP-immunized plus α-OX40 treated
mice the number of (CD44hiCD11ahi) CD4+ (∗∗p = 0.0014
and ∗∗p = 0.0045; respectively) and CD8+ (∗∗p = 0.0073 and
∗p = 0.0357; respectively) T cells were significantly increased
compared to GAP-immunized mice (Figure 5A). Also, when
we compared activated effector-type (CD44hiKLRG1hi) CD4+
and CD8+ T cells, we found that in the spleens of GAP-
immunized plus α-OX40 mice the number of (CD44hiKLRG1hi)
CD4+ T cells were significantly increased (∗p= 0.043) compared
to GAP-immunized mice (Figure 5B). Combined these results
suggest that enforced OX40 stimulation after a prime-boost
immunization does not only impact the expansion of antigen-
experienced effector CD4+ T cells, as was shown after a single
immunization, but also expands the pool of antigen-experienced
effector CD8+ T cells.
α-OX40 Treatment Increases IFN-γ and
TNF Producing CD4+ T Cells in Both Liver
and Spleen and Increases the Amount of
Sporozoite-Specific Antibodies After
Prime-Boost Gap Immunization
In order to study the impact of the α-OX40 treatment on the
cytokine production of the CD4+ and CD8+ T cells after prime-
boost immunization, we performed intracellular staining for
IFN-γ and TNF of hepatic leucocytes and splenocytes isolated
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FIGURE 5 | Increased effector T cell formation by α-OX40 treatment after prime-boost GAP immunization. (A) See Figure 4 for the time line of immunization and
collection of T cells. The upper panel shows the percentages of (CD44hiCD11ahi) CD8+ and CD4+ T cells in liver and spleen. The lower panel shows the total
number of (CD44hiCD11ahi) CD8+ and (CD44hiCD11ahi) CD4+ T cells in liver and spleen. A significant increase of (CD44hiCD11ahi) CD8+ cells (*p = 0.0357 and
**p = 0.0073) and (CD44hiCD11ahi) CD4+ (**p = 0.0045 and **p = 0.0014) was observed in both liver and spleen, in mice immunized with GAP plus α-OX40
compared to only GAP-immunized mice. Representative data is shown from 2 independent experiments with 6 mice per group. Significant difference by unpaired
t-test is indicated by not significant (n.s.) and significant; *p < 0.05 or **p < 0.01, ***p < 0.001. (B) The upper panel shows percentages of (CD44hiKLRG1hi) CD8+
and CD4+ T cells in liver and spleen in the different groups of mice. The lower panel shows the total number of (CD44hiKLRG1hi) CD8+ and (CD44hiKLRG1hi) CD4+
T cells. A significant increase of (CD44hiKLRG1hi) CD4+ T cells was observed in spleens of mice immunized with GAP plus α-OX40 compared to only
GAP-immunized mice (*p = 0.043, respectively). Representative data is shown from 2 independent experiments with 6 mice per group. Significant difference by
unpaired t-test is indicated by not significant (n.s.) and significant; *p < 0.05 or **p < 0.01, ***p < 0.001.
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7 days after the final immunization. Before staining cells were
stimulated in vitro for a period of 24 h with sporozoites. It has
been reported that treatment with anti-ARTC2 antibodies can
improve T cell survival and recovery after in vitro stimulation
consequently mice were treated with ARTC2 nanobodies 30min
before collection of the organs (Rissiek et al., 2014). We observed
a significant increase in IFN-γ producing CD4+ (∗∗p = 0.0065)
and CD8+ (∗∗p = 0.0018) T cells in the spleens of GAP-
immunized plus α-OX40 treated mice compared to GAP-
immunized mice. In the liver of GAP-immunized plus α-OX40
treated mice, there was an increase of IFN-γ producing CD4+
T cells (p = 0.0506) but not of CD8+ T cells. Further, we
observed a significant increase in TNF producing CD4+ T
cells in both liver (∗p = 0.0398) and spleen (∗∗p = 0.0068) of
GAP-immunized plus α-OX40 treated mice compared to GAP-
immunized mice but TNF production in CD8+ T cells was not
significantly different in either the liver or spleen (Figure 6A).
Taken together, these results show that α-OX40 treatment after
a prime-boost GAP immunization elicits a significant increase
in IFN-γ and TNF producing CD4+ T cells in both liver and
spleen of GAP-immunized plus α-OX40 treated mice compared
to GAP-immunized mice.
In addition to collecting organs at day 7 after the final
immunization, we also collected serum from these mice
to perform ELISA analysis with P. yoelii sporozoite lysate
to quantify parasite-specific IgG responses. This analysis
revealed that mice immunized with GAP sporozoites generate
sporozoite-specific antibody responses and that there is a
significant (∗p = 0.02, Student’s t-test) increase in the total
IgG produced in mice immunized with GAP plus α-OX40
treatment compared to mice immunized with only GAP
(Figure 6B).
DISCUSSION
Vaccination with live attenuated sporozoites can induce
protective immunity in humans but induction of sterile
protection requires immunization with multiple doses and
each dose consisting of relatively high numbers of sporozoites
(Hoffman et al., 2015; Hollingdale and Sedegah, 2017).
Enhancing the immunogenicity of whole sporozoite (wsp)
vaccines, for example by adding adjuvants, can be used to
both reduce the number of sporozoites per dose and the
number of vaccine doses, as well as directing the adaptive
immune response. We show in this study that treatment of
mice with an agonistic antibody against the T cell costimulatory
molecule OX40, a member of the tumor necrosis factor
receptor (TNFR) superfamily (AlShamkhani et al., 1996),
enhances protective immunity after immunization with GAP
sporozoites.
Previously it has been shown that targetingOX40 increases the
magnitude of T cell responses and improves T cell functionality
(Sugamura et al., 2004; Croft, 2010). OX40 is transiently
expressed on T cells following cognate interactions between
T cell receptors (TCRs) and antigen-major histocompatibility
(MHC) complexes on antigen presenting cells (APCs) (Croft,
2010). While OX40 is expressed on both activated CD4+ and
CD8+ T cells, OX40 expression on CD4+ T cells is greater
than CD8+ T cells and consequently α-OX40 treatment is
expected to exert its greatest effect on CD4+ T cells (Baum et al.,
1994; AlShamkhani et al., 1996; Croft, 2010). OX40 signaling
promotes T cell proliferation and survival, influences CD4+ T
cell differentiation into T helper subsets (Walker et al., 1999;
Murata et al., 2000; Soroosh et al., 2007; Song et al., 2008) and
is reported to reverse CD4+ T cell hypo-responsiveness (Bansal-
Pakala et al., 2001). While it has been previously described
that OX40 is expressed on activated human and rodent CD4T
cells after a malaria blood stage infection (Zander et al., 2015;
Goncalves-Lopes et al., 2016) no data had been reported on
the expression of OX40 on T cells after a sporozoite/liver
stage Plasmodium infection/immunization. We demonstrate
in this study that after GAP-sporozoite immunization OX40
expression was observed on activated (CD44hi) CD4+ and
CD8+ T cells in the liver. Similarly OX40 expression was
upregulated on activated CD4+ T cells in the spleen but not
observed on activated CD8+ T cells. We therefore hypothesized
that therapeutic ligation of OX40 during immunization with
attenuated Plasmodium sporozoites would increase parasite-
specific CD4+ and CD8+ T cell activity, limit the degree of T
cell exhaustion and improve T cell effector-memory formation,
all resulting in increased clearance of PyWT sporozoites/liver
stages.
To analyze the effect of adjuvants on wsp vaccination
approaches we first developed a model with a sub-saturating
immunization regiment, which we could use to measure
enhancement of protective immunity through the application
of adjuvants. In this study we demonstrate that a single
immunization with 2.5 and 5 × 104 sporozoites induces
partial protection as determined by an absence of sterile
protection after PyWT sporozoites challenge but a 1
day delay in the emergence of parasites in the blood
(prepatent period). A 1 day delay in prepatent period
has been correlated with a 10× reduction in parasites
released from the liver (Janse et al., 2006), indicating a 10×
increase in protective immunity compared to unimmunized
mice.
In cytomegalovirus (CMV) vaccination studies it was
found that the increase in vaccine potency can be achieved
by α-OX40 treatment through the expansion of both
antigen-specific CD4+ and CD8+ T cells (Panagioti et al.,
2017). A marked upregulation of OX40 is observed on
Plasmodium specific CD4+ T cells that are generated in
both human and rodent malaria blood stage infections
and, in rodent studies, α-OX40 treatment was shown to
increase parasite-specific memory CD4+ T cells resulting
in a reduced blood-stage infection (Zander et al., 2015,
2017; Goncalves-Lopes et al., 2016). However, prior to
this study the effects of OX40 treatment on immune
responses induced by wsp vaccination have not been
described.
Our analyzes of T cell responses in mice immunized with
a single dose of GAP parasites, showed an increase in total
WBC numbers in the livers and an increase in CD4+ effector
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FIGURE 6 | α-OX40 treatment increases IFN-γ and TNF producing CD4+ T cells in both liver and spleen and increases the amount of sporozoite-specific antibodies
after prime-boost GAP immunization. (A) See Figure 4 for the time line of immunization and collection of T cells. The upper panel shows percentage of IFN-γ and TNF
cytokine producer CD8+ and CD4+ T cells in liver and spleen after in vitro sporozoite re-stimulation. The second panel shown the total number of IFN-γ and TNF
cytokine producer CD8+ and CD4+ T cells in liver and spleen. Significant differences in both IFN-γ cytokine producer CD8+ and CD4+ T cells (**p = 0.0018 and **p
= 0.0065, respectively) were observed between spleens of α-OX40 treated and untreated mice. In addition, an increase in IFN-γ cytokine producer CD4+ T cells
(p = 0.0506) was observed in livers of treated mice compared to livers of untreated mice. Further, a significant differences of TNF producing CD4+ T cells in both liver
and spleen (*p = 0.0398 and **p = 0.0068, respectively) were observed between α-OX40 treated and untreated mice. Representative data is shown from 2
independent experiments with 6 mice per group. Significant difference by unpaired t-test is indicated by not significant (n.s.) and significant; *p < 0.05 or **p < 0.01,
***p < 0.001. (B) Quantification by ELISA of P. yoelii WT sporozoite-specific IgG obtained from naïve and prime-boost immunized mice with P. yoelii GAP (with or
without α-OX40 treatment). The concentration of the total IgG in the ELISA was quantified using the values for each sample based on the standard curve obtained
with defined concentrations of polyclonal antibodies against PyCSP (Bioss Antibodies Inc., USA).
(CD44hiCD11ahi) T cells in both liver and spleen of α-
OX40 treated mice compared to untreated mice. It has been
reported by Cooney et al. that T cells with a CD44hiCD11ahi
phenotype are indicative of antigen-experienced effector cells
in GAP-immunized BALB/c mice (Cooney et al., 2013). While
protective immunity after wsp immunization is thought to
largely dependent on the killing infected hepatocytes by CD8+
T cells and IFN-γ (Tarun et al., 2007; Douradinha and Doolan,
2011; Khan et al., 2012), adoptive transfer of CD4+ T cells
from GAP-immunized C57BL/6 mice was able to provide
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sterile protection to 50% of naïve animals against a WT
infection, indicating an important role for CD4+ T cells in
GAP induced immunity (Tarun et al., 2007). In addition,
protective immunity induced by sporozoites of a P. yoelii
GAP, similar to the one used in our study, was dependent
not only on CD8+ T cells but also CD4+ T cells (Murray
et al., 2015). Immune responses induced by P. yoelii GAPs
that arrest late into liver development (Butler et al., 2011)
are reported to involve both the cellular and humoral arm of
the adaptive immune response. Indeed, Keitany et al. showed
that functional antibodies are induced after immunization
with P. yoelii GAPs, which can inhibit sporozoite invasion
of liver cells and reduce intrahepatic parasite development
(Vanderberg and Frevert, 2004; Keitany et al., 2014; Sack et al.,
2014). Since enhancement of CD4+ T cell responses by OX40
stimulation may lead to an increase in humoral immunity we
examined total IgG responses generated in mice after prime-
boost GAP immunization, either with or without α-OX40
treatment. These studies revealed that anti-sporozoite antibodies
were generated after GAP immunization and significantly more
IgG was generated in mice immunized with GAP plus α-
OX40 treatment compared to mice immunized with only GAP.
This observation indicates that the increase in CD4+ T cells
after α-OX40 treatment may be directly contributing to B cell
maturation/activation.
We further examined the effect of α-OX40 treatment on
adaptive immune responses by analyzing immune responses in
mice that had received a boost immunization after the prime
immunization. After this prime-boost strategy we observed
an increase in total WBC numbers in livers and spleens of
both GAP-immunized plus α-OX40 and GAP-only immunized
mice. However, we observed a significant increase in effector
(CD44hiCD11ahi) CD4+ and CD8+ T cells in liver and spleen of
GAP-immunized plus α-OX40 treated mice compared to GAP-
only immunized mice. This is in contrast to the single prime
strategy where we only observed a significant in increase only
in effector (CD44hiCD11ahi) splenic and liver CD4+ T cells in
GAP-immunized plus α-OX40 treated mice. When we examined
the activation phenotype (CD44hiKLRG1hi) of these T cells in
liver and spleen, α-OX40 treatment significantly increased only
the number of activated CD4+ T cells and only those present
in the spleen. Additionally, we observed a significant increase in
IFN-γ producing CD4+ and CD8+ T cells in the spleen but not
in the liver (Murray et al., 2015). We also observed a significant
increase in TNF producing CD4+ T cells, but not CD8+ T cells,
in the liver and spleens of GAP-immunized plus α-OX40 treated
mice. Therefore CD4+ T cells in the spleen may contribute
to protective immunity either by enhancing humoral responses
targeting sporozoites invasion (Sack et al., 2014) or by enhancing
CD8+ T cell responses that target infected hepatocytes. Recently
it was reported, in mice that liver resident CD8+ T cells induced
by wsp vaccination may be primed in the spleen and their
conversion occurring after reencountering parasite antigen in the
liver (Fernandez-Ruiz et al., 2016). Our results indicate that the
increased protective immunity observed in GAP-immunized plus
α-OX40 treated mice acts primarily via enhanced CD4+ T cell
responses in the spleen. It is known that CD4+ T cell help is
necessary for an effective CD8+ T cell memory response against
non-inflammatory antigens, such as tumor cells and certain
pathogens that may not carry sufficient danger signals (Sun et al.,
2004). Mice depleted of CD4+ T cells during immunization with
sporozoites failed to exhibit a robust CD8+ T cell expansion
and were not protected against challenge (Weiss et al., 1993;
Overstreet et al., 2011). Murray et al. found that CD4+ T cell
help was also necessary to induce protection after immunization
with GAP sporozoites (Murray et al., 2015). OX40, in addition
to being a costimulatory receptor that potentiates proliferation,
survival, memory formation, and effector function of CD4+
and CD8+ T cells, can also overcome the suppressive activity
of regulatory T cells (Tregs) (Croft et al., 2009). Overcoming
immune suppression effects could also benefit the generation
of protective immunity after wsp vaccination as it has been
recently shown that wsp immunization, in particular after GAP
administered via the skin, can induce regulatory responses
(Haeberlein et al., 2017). Together, our results indicate that
improving CD4+ T cell activation enhances protective immunity
against malaria. Whether this CD4+ T cell stimulation acts
primarily by improving humoral responses targeting sporozoites
or by increasing CD8+ T cell responses against infected liver
cells and how these responses may contribute to formation of
immunological memory and duration of protection requires
further investigation.
A limited number of other studies have been performed
on the effect of adjuvants on protective immunity induced by
wsp immunization. In particular the use of the glycolipid α-
galactosylceramide (α-GalCer) (Gonzalez-Aseguinolaza et al.,
2002) and its analog 7DW8-5 have been analyzed (Li et al.,
2015). Co-administration of these molecules with sporozoites
resulted in enhanced recruitment and activation/maturation
of dendritic cells in lymph nodes draining the site of
vaccine administration and thereby enhancing parasite-specific
T cell immunogenicity. Although the possible use of certain
adjuvants in human vaccination studies may be difficult due
to costs, applicability or side-effects, these pre-clinical studies
provide useful information of the largely unknown mechanisms
underlying protective immunity. Although α-OX40 treatment
is currently in clinical trials for cancer immunotherapy, the
use of antibody-based α-OX40 treatment may, for vaccines
for the developing world, be unrealistic as they are likely
to be too expensive. Other (protein based) agents that
can stimulate costimulatory responses, including agonists of
OX40 are being developed as potential adjuvants in vaccine
development. For example, combination therapy using the
protein ligand of OX40, OX40L, fused to a cancer vaccine
have been shown to reduce breast cancer metastasis, by
enhancing antigen specific CD4+ and CD8+ T cell responses
and inhibiting immunosuppressive Treg responses (Malamas
et al., 2017). The co-administration of proteins like OX40L
which are likely to be cheaper and easier to produce,
may therefore be more practical and feasible approaches to
pursue. In conclusion, this study demonstrates how specific
immune response to vaccination coupled with activation of
costimulatory molecules on the surface of T cells, can enhance
protective immunity after wsp immunization and merits further
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investigation to see if such approaches not only increase the
magnitude but also the breadth of an immune responses after
vaccination.
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